Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the safety, tolerability and local tolerance, and
to investigate the plasma levels and terminal elimination half life of MCI-186, and to review
the routine clinical and neurological assessments data of MCI-186 in subjects with acute
ischemic stroke.